In preclinical prostate carcinoma in the bone, Rad-223 eradicated effectively micro-tumors but macro-tumors persisted and expanded. The data point to application of Rad-223 in secondary prevention of early bone-metastatic disease and regimens co-targeting the tumor core.Peter Friedl, theme Cancer development and immune defense, and colleagues, published these findings in the Journal of the National Cancer Institute (JNCI).
Bone-targeting radiotherapy with Radium-223 (Rad-223), a radioisotope emitting genotoxic alpha-radiation with limited tissue penetrance (∼100 µm), prolongs the survival of patients with metastatic prostate cancer (PCa). Confoundingly, the clinical response to Rad-223 is often followed by detrimental relapse and progression, and whether Radium-223 causes tumor-cell directed cytotoxicity in vivo remains unclear. In a joint effort between the Radboudumc and the MD Anderson Cancer Center, they show that limited radiation penetrance in situ defines outcome.
They tested the Radium-223 overall response in prostace cancer in mouse bones and applied intravital microscopy and in silico modeling to predict Rad-223 effectiveness in lesions of different sizes. Rad-223 caused profound cancer cell lethality along the bone interface but not the more distant tumor core. In silico simulations predicted greater efficacy of Rad-223 on single-cell lesions (eradication rate: 88.0%) and minimal effects on larger tumors (no eradication, 16.2% growth reduction in tumors of 27,306 cells), further confirmed in vivo tumors in mice. Micro-tumors showed severe growth delay or eradication in response to Rad-223, whereas macro-tumors persisted and expanded.
The relative inefficacy in controlling large tumors points to application of Rad-223 in secondary prevention of early bone-metastatic disease and regimens co-targeting the bone niche together with the tumor core.
Related news items
High school science education program Immunology and Programming23 April 2019
International PhD candidates Joshua Gillard, Dorien Feyaerts and Yessica Rodriguez of the Laboratory of Medical Immunology (LMI), recently developed and implemented an exciting 4-day science challenge to teach vaccinology, immunology, and programming at the Lorenz Lyceum high school in Arnhem.read more
EU funded project BIOMAP led by Ellen van den Bogaard12 April 2019
Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.read more
Interacting non-specific immunological effects of BCG and Tdapf vaccinations5 April 2019
In a randomized trial Mihai Netea and colleagues aim to investigate the non-specific immunological effects of BCG and DTP-containing vaccines on the immune response to unrelated pathogens. They have published their findings in Clinical Infectious Diseases.read more
Size matters: Miniaturised interaction proteomics with ultra-low input requirements4 April 2019
Cristina Furlan and René Dirks from the groups of Michiel Vermeulen and Hendrik Marks, theme Cancer development and immune defense, teamed up to develop a low-input interaction proteomics platform, called on-chip AP-MS. They published these findings in Nature Communications.read more